Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 2/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 4/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.32 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | RHEB | Q15382 | 1/20 | 0.31 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27247517 | 1.00 | PDCD1 (0.34) | PDCD1CD274MAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL30946084 | 0.98 | PDCD1 (0.34) | PDCD1CD274MAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL27247005 | 0.98 | PDCD1 (0.34) | PDCD1CD274MAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL30946183 | 0.89 | MAPK1 (0.34) | MAPK1RAB9ANPC1KMT2ADGAT2 | |
| SCHEMBL27247302 | 0.88 | MAPK1 (0.34) | MAPK1RAB9ANPC1KMT2ADGAT2 | |
| SCHEMBL30946178 | 0.88 | MAPK1 (0.34) | MAPK1RAB9ANPC1KMT2ADGAT2 | |
| SCHEMBL30920240 | 0.86 | EPHX2 (0.36) | MAPK1CYP2C9EPHX2CYP2J2DGAT2 | |
| SCHEMBL30920318 | 0.86 | MAPK1 (0.35) | MAPK1RAB9ASMN1; SMN2TP53HPGD | |
| SCHEMBL27247142 | 0.86 | MAPK1 (0.35) | MAPK1RAB9ASMN1; SMN2TP53HPGD | |
| SCHEMBL30946143 | 0.85 | PDCD1 (0.41) | PDCD1CD274SMN1; SMN2IDH1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199546-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | HERCULES CAPITAL, INC., AS AGENT | 2024-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199546-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | SLC6A19, SLC2A9, SLC6A3 | PDCD1 4725/4885CD274 4801/4885MAPK1 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.